TriOar is focusing on developing
its proprietary platform technologies for
next-generation antibody therapeutics.

TROCAD™ : TriOar's Conditionally Acitavatable Domain
"TROCAD™" features a stable molecular structure, allows for integration with various modalities and enables a wide range of applications.
TROCAD™ is one of TriOar's new modular platforms that is designed not only to actively deliver antibody drugs to the TME (Tumor microenvironment) but also to undergo rapid transformation into active molecules within the TME.
TROCAD™ can be applied to various modalities, and is designed to ensure molecular stability, and versatility for general use.
TROSIG™ : TriOar's Self-Immolative Group
"TROSIG™" Stable and
Efficient Novel Linker-Toxin System.
TROSIG™ is a ready-to-use novel linker-toxin system.
The new core structure of the self-immolative group (SIG), a crucial factor determining the biological characteristics and efficacy of ADC drugs, has been designed to accomodate a wide range of payolads containing various functional groups (FG) for optimal ADC development. Furthermore, the advantages of TROSIG™ include rapid and efficient drug release at low pH in lysosomes, excellent solubility, and outstanding stability in biological environments.
Mechanism of Action
TriOar platform targets cancer lesions quickly and specifically, exerting its therapeutic effects with an enhanced therapeutic index.
It can be used for various targets and modalities, with applications extending to various disease categories, including cancer, as well as other indications such as inflammation and autoimmune diseases.